Supernus, Inc. is a biopharmaceutical company that develops and commercializes treatments for central nervous system (CNS) diseases. The company operates through two main business segments following the merger of Supernus Pharmaceuticals and Indivior Pharmaceuticals. The Indivior segment focuses on opioid use disorder (OUD) treatments, with its core products being SUBLOCADE, a monthly buprenorphine extended-release injection, and SUBOXONE Film, a sublingual film containing buprenorphine and naloxone. The company also distributes SUBUTEX Tablets in international markets. The Supernus segment develops therapies for neurological and psychiatric conditions, including migraine prevention, epilepsy, Parkinson's disease, and ADHD. Its marketed products include Qelbree for ADHD. The company serves patients and healthcare providers primarily in the United States, with additional product availability in Canada, Australia, France, and Germany. Supernus, Inc. was formed through the merger of Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., which completed on November 2, 2026. Indivior was originally incorporated as a standalone business in 2014 following a demerger from Reckitt Benckiser Group PLC. The company also acquired Sage Therapeutics.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage supernus.com
Sector Healthcare IR page ir.supernus.com/investor-relations
Tags
central nervous system, opioid use disorder, adhd, migraine, epilepsy, parkinson's disease, buprenorphine, specialty pharmaceuticals, us markets, international markets, SUBLOCADE, SUBOXONE Film, SUBUTEX Tablet, Qelbree, Sage Therapeutics, Indivior Pharmaceuticals, Supernus Pharmaceuticals, INSUPPORT Community Reentry Program
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable —
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Filed figures

Figure Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — 254M 254M 253M
↳ YoY growth 0% -0.4%
Borrowings, current (USD) — — 3M 18M 29M
Borrowings, non-current (USD) — — 237M 315M 290M
Lease liabilities (USD) — — 43M 42M 32M
Cash and deposits (USD) 1.1B 774M 316M 319M 195M
Right-of-use assets (USD) — — 40M 39M 26M
Net debt (borrowings + leases - cash) (USD) — — -33M 56M 156M
Cash flow detail
Operating cash flow (USD) — -4M -300M 36M -27M
Purchases of property, plant and equipment (USD) — -5M -8M -29M -66M
Purchases of intangible assets (USD) — 0.00 -45M -2M -1M
Change in receivables (cash effect) (USD) — -21M -33M -1M 3M
Change in inventories (cash effect) (USD) — -30M -15M -45M 18M
Share buybacks (cash effect) (USD) — -90M -33M -173M -11M
Interest paid (cash effect) (USD) — -18M -26M -32M -34M
Income taxes paid (cash effect) (USD) — -57M -32M -46M -38M
Share-based compensation (USD) — 16M 21M 24M 26M
Operating cash flow before change in receivables (USD) — 17M -267M 37M -30M
Free cash flow (OCF - PPE - intangibles) (USD) — -9M -353M 5M -94M
Income detail
Research and development expense (USD) 52M 72M 106M 107M 97M
Total comprehensive income (USD) — -50M -127M -4M 216M
Comprehensive income to owners (USD) — -50M -127M -4M 216M
Reported Mar 3, 2025 Mar 3, 2025 Mar 3, 2025 Mar 3, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

News

Indivior Pharmaceuticals, Inc. — Other Events Bull 0 Bear 0 Routine

Other

Pursuant to the terms of the Indenture, dated March 17, 2026, by and between Supernus, Inc. (f/k/a Indivior Pharmaceuticals, Inc.; the “Company” or the “Registrant”) and U.S. Bank Trust Company, National Association (the “Indenture”), governing the Company's 0.625% Convertible Senior Notes due 2031 (the “Notes”), as a result of the Special Dividend that was declared by the Company’s board on September 16, 2026, the conversion rate per $1,000 principal amount of Notes has been increased from 24.0033 shares of the Company’s common stock to 30.9355 shares of the Company’s common stock, which reflects a conversion price of approximately $32.33 per share. The conversion rate is subject to customary adjustments upon the occurrence of certain events as described in the Indenture. No bondholders converted their bonds for common stock.

November 2, 2026 at 9:18 AM EST

PDF Version

  • Merger positions Supernus as a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, enhanced financial flexibility and a differentiated pipeline

  • Significantly enhances cash flow profile and scale, unlocking greater capacity to resource growth-driving products, advance CNS pipeline, and pursue strategic opportunities

  • Combined entity will operate as Supernus, Inc. and begin trading on the Nasdaq Global Market under the ticker symbol “SUPN” on November 3, 2026

ROCKVILLE, Md., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN)1 today announced the successful completion of the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (Indivior). The combination officially launches Supernus, Inc., a leading diversified biopharmaceutical company dedicated to treating those living with central nervous system (CNS) diseases.

Supernus, Inc. Creates Immediate Scale and Expanded Capabilities

  • A Diversified Commercial Platform: An 11-product portfolio spans opioid use disorder, psychiatry, and neurology, and includes five core growth drivers – SUBLOCADE®, Qelbree®, GOCOVRI®, ONAPGO®, and ZURZUVAE® – that provide a durable foundation for long-term revenue expansion.

  • Established Financial Scale and Enhanced Cash Flow: Financial capacity to pursue further growth opportunities, including driving growth in its commercial portfolio, advancing its novel pipeline, and pursuing future business.

“Today marks a transformative milestone as we officially bring together two organizations united by a shared dedication to those living with complex neurological conditions,” said Jack Khattar, President and CEO of Supernus, Inc. “As one team, we are committed to expanding meaningful treatments for patients, executing seamlessly, and delivering long-term value for our shareholders.”

Tony Kingsley, Chair of the Board of Directors of Supernus, Inc., added, "This combination brings together best-in-class commercial capabilities, leading CNS therapies, and a strong financial foundation. We believe the combined company is exceptionally well positioned to pursue long-term growth while maintaining disciplined capital allocation and a commitment to creating shareholder value."

The Merger and Transaction Details Under the terms of the definitive merger agreement, Supernus Pharmaceuticals, Inc. stockholders received 1.5401 common shares of Indivior Pharmaceuticals, Inc. for each share of Supernus Pharmaceuticals, Inc. they owned.

Stockholders of Indivior immediately prior to the closing of the merger will receive a one-time special cash dividend of $1.0 billion in the aggregate as previously announced. To finance the dividend to Indivior stockholders, the companies utilized a previously secured debt commitment of $650 million through a term loan facility provided by Citibank N.A., with the remaining portion funded by existing cash on hand of the combined company.

Upon the close of the transaction, former Indivior stockholders own approximately 56.5% of the combined company, and former Supernus Pharmaceuticals, Inc. stockholders own approximately 43.5% of the combined company, on a fully diluted basis.

Leadership and Governance Supernus Pharmaceuticals’ current headquarters in Rockville, Md., will serve as the combined company’s global headquarters. Jack Khattar will serve as President, Chief Executive Officer and a member of the Board of Directors of the combined company, and Tony Kingsley, previously a member of Indivior’s Board of Directors, will serve as Board Chair. The combined company's Board of Directors has a total of eight directors, including four directors from each of the legacy companies.

Advisors Cantor Fitzgerald & Co. served as lead financial advisor to Supernus Pharmaceuticals. Wells Fargo also served as an additional financial advisor to Supernus Pharmaceuticals. Saul Ewing LLP served as legal counsel to Supernus Pharmaceuticals and Morgan Lewis UK served as legal advisors to Supernus Pharmaceuticals with respect to certain ex-US matters.

Jefferies LLC and Piper Sandler & Co. served as joint financial advisors to Indivior and Goodwin Procter LLP served as legal counsel to Indivior. Citi also provided financial advice to Indivior, and Citibank, N.A. provided committed financing in support of the transaction.

Additional information about the transaction can be found on the Supernus website, which is listed below.

About Supernus, Inc. Supernus, Inc. is a leading, diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases.

Our commercial portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Backed by strong commercial capabilities and scientific expertise, we are committed to continuous innovation, advancing a robust pipeline of novel product candidates to deliver meaningful outcomes for CNS patients.

On October 15, 2026, Indivior Pharmaceuticals, Inc. (“Indivior”) held a special meeting of its stockholders (the “Indivior Special Meeting”). At the close of business on September 4, 2026, the record date for the Indivior Special Meeting, there were 118,031,934 shares of Indivior common stock (“Indivior Shares”) outstanding and entitled to vote at the Indivior Special Meeting, of which 91,206,182 Indivior Shares were present in person or represented by proxy at the Indivior Special Meeting, representing 77.27% of Indivior Shares outstanding and entitled to vote, which constituted a quorum to conduct business at the Indivior Special Meeting. At the Indivior Special Meeting, Indivior’s stockholders approved the proposal described below and which is described in greater detail in Indivior’s definitive joint proxy statement/prospectus filed with the Securities and Exchange Commission on September 11, 2026.

Prompts

Supernus, Inc. (ticker SUPN), listed in United States.

Company History

Date Change Detail
Nov 3, 2026 Renamed INDIVIOR PHARMACEUTICALS, INC. → Supernus, Inc.
Nov 3, 2026 Merged Absorbed SUPERNUS PHARMACEUTICALS, INC. (CIK 1356576) and took its name. That company's filings from before the merger are its own, not shown here.
Nov 2, 2026 Continued as Carried on as Supernus, Inc. (CIK 1625297), a new registrant. Its figures are its own.
Nov 2, 2026 Acquired Acquired Supernus Pharmaceuticals, Inc. (CIK 1356576). Its filings from before the deal are on its own company page, not shown here.
Jan 26, 2026 Renamed INDIVIOR PLC → INDIVIOR PHARMACEUTICALS, INC.
— Predecessor Predecessor Indivior Pharmaceuticals, Inc. (CIK 1625297) filed under its own registration; its figures are on its own company page, not shown here.
— Former tickers INDV

ETFs Holding Supernus, Inc.

ETF Weight in ETF Shares Market value As of
SIXS 0.96% 47,573 $ 1.389M Nov 12, 2026
SIXL 0.34% 24,707 $ 721.444K Nov 12, 2026
JMEE 0.05% 48,061 $ 1.396M Nov 17, 2026